Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Atlas Molecular Pharma General Information
Successfully completed Phase 1 clinical trial for ATL-001 in Congenital Erythropoietic Porphyria, demonstrating safety and tolerability in 40 healthy volunteers. Poised to begin Phase 2 trials in the United States.
Contact Information
Primary Industry
Biotech
Corporate Office
Derio, Basque Country
Spain
Spain
Drug Pipeline
ATL-001
Phase 1Key Partnerships
Atlas Molecular Pharma Funding
No funding data available
To view Atlas Molecular Pharma's complete valuation and funding history, request access »